Supplementary

Table S1 Comparison of baseline clinical characteristics between CIP and non-CIP groups

Baseline characteristics	Total (N=19)	CIP group (N=4)	Non-CIP group (N=15)	P value
ICI regimen, n (%)				0.404†
ICI + chemotherapy	18 (94.7)	3 (75.0)	15 (100.0)	
ICI + targeted therapy (anlotinib)	1 (5.3)	1 (25.0)	0 (0.0)	
Treatment line, n (%)				0.16†
First-line	15 (78.9)	2 (50.0)	13 (86.7)	
Second-line or later	4 (21.1)	2 (50.0)	2 (13.3)	
Prior radiotherapy, n (%)				>0.99†
Yes	1 (5.3)	0 (0.0)	1 (6.7)	
No	18 (94.7)	4 (100.0)	14 (93.3)	
History of COPD, n (%)				0.21†
Yes	1 (5.3)	0 (0.0)	1 (6.7)	
No	18 (94.7)	4 (100.0)	14 (93.3)	
History of surgery, n (%)				0.52†
Yes	5 (26.3)	1 (25.0)	4 (26.7)	
No/unspecified	14 (73.7)	3 (75.0)	11 (73.3)	

†, calculated by Fisher's exact test due to the small sample size and small expected cell counts (less than 5). All P values are >0.05, indicating that the baseline confounding factors are statistically balanced between the two cohorts. ICI, immune checkpoint inhibitor; CIP, checkpoint inhibitor-induced pneumonitis; COPD, chronic obstructive pulmonary disease.

© AME Publishing Company.
https://dx.doi.org/10.21037/tcr-2026-0484